ClinConnect ClinConnect Logo
Search / Trial NCT05194527

The Detrimental Course of Acute Intestinal Ischemia

Launched by MAASTRICHT UNIVERSITY · Jan 4, 2022

Trial Information

Current as of August 22, 2025

Unknown status

Keywords

Acute Mesenteric Ischemia Volatile Organoic Compounds Plasma/Serum Biomarkers Sm22 Villin 1 I Fabp Diagnosis

ClinConnect Summary

INTRODUCTION AND RATIONALE Acute intestinal ischemia remains a common clinical emergency with short-term mortality up to 80% and is often highly underestimated. , , It is a life-threatening clinical condition of diminished blood flow towards the gut, resulting in decreased supply of oxygen and nutrients to the intestinal tissue. Prolonged periods of ischemia are associated with disruption of the intestinal wall that normally functions as an important barrier. , The intestinal wall is composed of different layers and has a multitude of functions, such as the absorption of nutrients as well a...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years
  • All consecutive patients admitted to one of the participating medical centers emergency departments (ED) or at the intensive care unit (ICU) (see 4.1 Population Base) with clinical suspicion of acute intestinal ischemia, which is based on;
  • clinical manifestation;
  • physical examination by the physician;
  • laboratory measurements;
  • physician's consideration to perform computed tomography (CT)-scan
  • Exclusion Criteria:
  • A subject who meets any of the following criteria will be excluded from participation in this study:
  • Age ≤ 18 years In order to evaluate the performance of the panel of markers for the acute intestinal ischemia in clinical practice, the study population must resemble the clinical patient population as closely as possible

About Maastricht University

Maastricht University is a leading academic institution in the Netherlands, renowned for its innovative approach to research and education in the health sciences. With a strong emphasis on interdisciplinary collaboration, the university actively engages in clinical trials that aim to advance medical knowledge and improve patient outcomes. Maastricht University leverages its state-of-the-art facilities and expertise in various fields, including biomedical research, public health, and clinical practice, to conduct high-quality clinical studies that adhere to rigorous ethical standards. Committed to translating research findings into real-world applications, the university plays a pivotal role in addressing contemporary health challenges and enhancing healthcare delivery.

Locations

Leuven, Vlaams Brabant, Belgium

Groningen, , Netherlands

Apeldoorn, Gelderland, Netherlands

Maastricht, Limburg, Netherlands

Amsterdam, Noord Holland, Netherlands

Amsterdam, Noord Holland, Netherlands

Patients applied

0 patients applied

Trial Officials

Annet Duivenvoorden, MSc

Study Chair

Maastricht University

Kaatje Lenaerts, PhD

Principal Investigator

Maastricht University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials